Advertisement

Neurologic manifestations of elderly patients with cancer

  • Bernardo Cacho-Díaz
  • Nydia A. Lorenzana-Mendoza
  • Gervith Reyes-Soto
  • José A. Ávila-Funes
  • Ana P. Navarrete-Reyes
Article
  • 26 Downloads

Abstract

Background

The incidence of cancer is an age-related phenomenon; therefore, the interest on clinical manifestations, diagnostic approach and treatment strategies for older patients diagnosed with cancer has increased lately. Neurologic symptoms are one of the main reasons for consultation and a common cause of decreased quality of life among cancer patients.

Aims

To identify the neurologic manifestations of patients ≥ 65 years of age diagnosed with cancer and compare them to those presented by a younger population.

Methods

Cross-sectional study of cancer patients referred to neuro-oncologic consultation at a Cancer Center. Sociodemographic, health and oncologic characteristics were obtained through clinical interviews. Clinical symptoms and final diagnoses were also recorded. Bivariate logistic regression analyses were carried out.

Results

More than 17,000 neuro-oncologic consultations in 3015 patients were given, 27% (n = 811) of them were ≥ 65 years of age. Most frequent primary neoplasms in elderly patients were: breast cancer, hematologic neoplasms, gynecological, urologic, skin and head and neck cancers. Elderly patients had an increased risk of having the following diagnoses: abnormal movements, stroke, peripheral vertigo, dementia, degenerative spine disorder, and delirium.

Discussion

Elderly patients are considered a vulnerable population. The present study found that the main neoplasms associated with neurological manifestations are similar to the reported previously. We described the main symptoms that led to a neuro-oncological assessment. Moreover, we enlisted the final diagnoses made on elderly patients and compared them with others reports. To the best of our knowledge, this study provides valuable information, since there is scarce evidence in the literature about this topic.

Conclusion

Identifying the frequency and correlation of neurologic manifestations in older cancer patients will allow for the implementation of timely multidisciplinary care in an attempt to improve these patients’ health-related quality of life.

Keywords

Elderly Cancer Neuro-oncology Neoplasms Quality of life 

Notes

Author contributions

BC-D: study concepts, study design, data acquisition, quality control of data and algorithms. NAL-M, GR-S: data analysis and interpretation, statistical analysis, manuscript preparation. JAÁ-F, APN-R: manuscript editing and manuscript review.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Compliance with ethical standards

Conflict of interest

The authors declare no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Institutional ethics and scientific committee approved this research.

Human and animal rights

This article does not contain any studies with animals performed by any of the authors.

Informed consent

For this type of study formal consent is not required.

References

  1. 1.
    Parry C, Kent EE, Mariotto AB et al (2011) Cancer survivors: a booming population. Cancer Epidemiol Biomark Prev 20:1996–2005.  https://doi.org/10.1158/1055-9965 CrossRefGoogle Scholar
  2. 2.
    Berger NA, Savvides P, Koroukian SM et al (2006) Cancer in the elderly. Trans Am Clin Climatol Assoc 117:147–155PubMedPubMedCentralGoogle Scholar
  3. 3.
    Yanick R, Ries LA (2000) Aging and cancer in America: demographic and epidemiologic perspectives. Hematol Oncol Clin North Am 14:17–23.  https://doi.org/10.1016/S0889-8588(05)70275-6 CrossRefGoogle Scholar
  4. 4.
    Mohile SG, Hurria A, Cohen HJ et al (2016) Improving the quality of survivorship for older adults with cancer. Cancer 122:2459–2568.  https://doi.org/10.1002/cncr.30053 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Anisimov VN (2003) The relationship between aging and carcinogenesis: a critical appraisal. Crit Rev Oncol Hematol 45:277–304.  https://doi.org/10.1016/S1040-8428(02)00121-X CrossRefPubMedGoogle Scholar
  6. 6.
    DePinho RA (2000) The age of cancer. Nature 408:248–254.  https://doi.org/10.1038/35041694 CrossRefPubMedGoogle Scholar
  7. 7.
    Eitan E, Hutchison ER, Mattson MP (2014) Telomere shortening in neurological disorders: an abundance of unanswered questions. Trends Neurosci 37:256–263.  https://doi.org/10.1016/j.tins.2014.02.010 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Peters R (2006) Ageing and the brain. Postgrad Med J 82:84–88.  https://doi.org/10.1136/pgmj.2005.036665 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Anderton BH (2002) Ageing of the brain. Mech Ageing Dev 123:811–817CrossRefPubMedGoogle Scholar
  10. 10.
    Gilbert MR, Grossman SA (1986) Incidence and nature of neurologic problems in patients with solid tumors. Am J Med 81:951–954CrossRefPubMedGoogle Scholar
  11. 11.
    Clouston PD, DeAngelis LM, Posner JB (1992) The spectrum of neurological disease in patients with systemic cancer. Ann Neurol 31:268–273.  https://doi.org/10.1002/ana.410310307 CrossRefPubMedGoogle Scholar
  12. 12.
    Cacho-Diaz B, Reyes-Soto G, Monroy-Sosa A et al (2016) Neurological manifestations in patients with cancer: more than 17,000 reasons for consultation. Rev Neurol 62:449–454PubMedGoogle Scholar
  13. 13.
    Khasraw M, Posner JB (2010) Neurological complications of systemic cancer. Lancet Neurol 9:1214–1227.  https://doi.org/10.1016/S1474-442(10)/70220-9 CrossRefPubMedGoogle Scholar
  14. 14.
    Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montelio MJ, Housman MG, Escarce JJ (2003) Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21:1383–1389.  https://doi.org/10.1200/JCO.2003.08.010 CrossRefPubMedGoogle Scholar
  15. 15.
    Wildiers H, Tryfonidis K, Dal Lago L et al. (2018) Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. Lancet Oncol 19:323–36.  https://doi.org/10.1016/S1470-2045(18)30083-4 CrossRefPubMedGoogle Scholar
  16. 16.
    Aparicio T, Lavau-Denes S, Phelip JM et al (2015) Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001–02). Ann Oncol 27:121–127  https://doi.org/10.1093/annonc/mdv491 CrossRefPubMedGoogle Scholar
  17. 17.
    Corre R, Greillier L, Le Caër H et al (2016) Use of a comprehensive geriatric assessment for the management of elderly patients with advanced non–small-cell lung cancer: the phase III randomized ESOGIA-GFPC-GECP 08-02 study. J Clin Oncol 34:1476–1483  https://doi.org/10.1200/JCO.2015.63.5839 CrossRefPubMedGoogle Scholar
  18. 18.
    Hurria A, Levit LA, Dale W et al (2015) Improving the evidence base for treating older adults with cancer: American Society of Clinical Oncology Statement. J Clin Oncol 33:3826–3833.  https://doi.org/10.1200/JCP.2015.63.0319 CrossRefPubMedGoogle Scholar
  19. 19.
    Tesarova P (2016) Specific aspects of breast cancer therapy of elderly women. Biomed Res Int 2016:1381695.  https://doi.org/10.1155/2016/1381695 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Gachet J, Girre V, Brain E et al (2010) Outcome of older patients with breast cancer with brain metastases. J Clin Oncol 28:e11501–e11501.  https://doi.org/10.1200/jco.2010.28.15_suppl.e11501 CrossRefGoogle Scholar
  21. 21.
    Kaplan JG, DeSouza TG, Farkash A et al (1990) Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol 9:225–229CrossRefPubMedGoogle Scholar
  22. 22.
    Giglio P, Gilbert MR (2010) Neurologic complications of cancer and its treatment. Curr Oncol Rep 12:50–59.  https://doi.org/10.1007/s11912-009-0071-x CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Waggoner SE (2003) Cervical cancer. Lancet 361:2217–2225.  https://doi.org/10.1016/S0140-6736(03)13778-6 CrossRefPubMedGoogle Scholar
  24. 24.
    Cacho-Díaz B, Lorenzana-Mendoza NA, Michel-Ortega RM et al (2016) Central nervous system metastases in patients with cervical carcinoma. Int J Gynecol Cancer 26:1686–1689.  https://doi.org/10.1097/IGC.0000000000000827 CrossRefPubMedGoogle Scholar
  25. 25.
    Ferlay J, Soerjomataram I, Dikshit R et al (2012) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN. Int J Cancer 136:E359–E386.  https://doi.org/10.1002/ijc.29210 CrossRefGoogle Scholar
  26. 26.
    Smith A, Howell D, Patmore R et al (2011) Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer 105:1684–1692.  https://doi.org/10.1038/bjc.2011.450 CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Ersbøll J, Schultz HB, Thomsen BL et al (1985) Meningeal involvement in non-Hodgkin’s lymphoma: symptoms, incidence, risk factors and treatment. Scand J Haematol 35:487–496CrossRefPubMedGoogle Scholar
  28. 28.
    Lewis DR, Chen HS, Cockburn MG et al (2017) Early estimates of SEER cancer incidence, 2014. Cancer 123:2524–2534.  https://doi.org/10.1002/cncr.30630 CrossRefPubMedGoogle Scholar
  29. 29.
    Smith BD, Smith GL, Hurria A et al (2009) Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 27:2758–2765.  https://doi.org/10.1200/JCP.2008.20.8983 CrossRefPubMedGoogle Scholar
  30. 30.
    Guancial E, Roussel B, Bergsma D et al (2015) Bladder cancer in the elderly patient: challenges and solutions. Clin Interv Aging 10:939–949.  https://doi.org/10.2147/CIA.S74322 PubMedPubMedCentralGoogle Scholar
  31. 31.
    Berneking A, Rosevear H, Askeland E et al (2013) Morbidity and mortality of octogenarians following open radical cystectomy using a standardized reporting system. Can J Urol 20:6826–6831PubMedGoogle Scholar
  32. 32.
    Malaguarnera G, Giordano M, Cappellani A et al (2013) Skin cancers in elderly patients. Anticancer Agents Med Chem 13:1406–1411CrossRefPubMedGoogle Scholar
  33. 33.
    Liao B, Shroff S, Kamiya-Matsuoka C et al (2014) Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro-Oncol 16:589–593.  https://doi.org/10.1093/neuonc/nou001 CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA A Cancer J Clin 55:74–108CrossRefGoogle Scholar
  35. 35.
    Owonikoko TK, Ragin CC, Belani CP et al (2007) Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol 25:5570–5577.  https://doi.org/10.1200/JCO.2007.12.5435 CrossRefPubMedGoogle Scholar
  36. 36.
    Flannery TW, Suntharalingam M, Regine WF et al (2008) Long-term survival in patients with synchronous, solitary brain metastasis from non–small-cell lung cancer treated with radiosurgery. Int J Radiat Oncol Biol Phys 72:19–23.  https://doi.org/10.1016/j.ijrobp.2007.12.031 CrossRefPubMedGoogle Scholar
  37. 37.
    Mohile SG, Fan L, Reeve E et al (2011) Association of cancer with geriatric syndromes in older medicare beneficiaries. J Clin Oncol 29:1458–1464.  https://doi.org/10.1200/JCO.2010.31.6695 CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Wasserstrom WR, Glass JP, Posner JB (1982) Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 49:759–772CrossRefPubMedGoogle Scholar
  39. 39.
    Extermann M, Hurria A (2007) Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 25:1824–1831.  https://doi.org/10.1200/JCO.2007.10.6559 CrossRefPubMedGoogle Scholar
  40. 40.
    Vigliani MC, Duyckaerts C, Hauw JJ et al (1999) Dementia following treatment of brain tumors with radiotherapy administered alone or in combination with nitrosourea-based chemotherapy: a clinical and pathological study. J Neurooncol 41:137–149CrossRefPubMedGoogle Scholar
  41. 41.
    Lawlor PG, Gagnon B, Mancini IL et al (2000) Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study. Arch Intern Med 160:786–794CrossRefPubMedGoogle Scholar
  42. 42.
    Hamaker ME, Jonker JM, de Rooij SE et al (2012) Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a. systematic review. Lancer Oncol 13:e437–e444.  https://doi.org/10.1016/S1470-2045(12)70259-0 CrossRefGoogle Scholar
  43. 43.
    Clegg A, Young J, Iliffe S et al (2013) Frailty in elderly people. Lancet 381:752–62.  https://doi.org/10.1016/S0140-6736(12)62167-9 CrossRefPubMedGoogle Scholar
  44. 44.
    Rogers L (2010) Cerebrovascular complications in patients with. Cancer Semin Neurol 30:311–319.  https://doi.org/10.1055/s-0030-1255224 CrossRefPubMedGoogle Scholar
  45. 45.
    Bang OY, Seok JM, Kim SG et al (2011) Ischemic stroke and cancer: stroke severely impacts cancer patients, while cancer increases the number of strokes. J Clin Neurol 7:53–59.  https://doi.org/10.3988/jcn.2011.7.2.53 CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Ojemann RG, Heros RC (1983) Spontaneous brain hemorrhag. Stroke 14:468–475CrossRefPubMedGoogle Scholar
  47. 47.
    Weinrich S, Sarna L (1994) Delirium in the older person with cancer. Cancer 74(7 Suppl):2079–2091CrossRefPubMedGoogle Scholar
  48. 48.
    Saiz A, Graus F (2010) Neurologic complications of hematopoietic cell transplantation. Semin Neurol 30:287–295.  https://doi.org/10.1055/s-0030-1255218 CrossRefPubMedGoogle Scholar
  49. 49.
    Tuma R, DeAngelis LM (2000) Altered mental status in patients with cancer. Arch Neurol 57:1727–1731CrossRefPubMedGoogle Scholar
  50. 50.
    Croft PB, Wilkinson M (1965) The incidence of carcinomatous neuromyopathy in patients with various types of carcinoma. Brain 88:427–434CrossRefPubMedGoogle Scholar
  51. 51.
    Currie S, Henson RA, Morgan HG et al (1970) The incidence of the non-metastatic neurological syndromes of obscure origin in the reticuloses. Brain 93:629–640CrossRefPubMedGoogle Scholar
  52. 52.
    Antoine JC, Camdessanché JP (2007) Peripheral nervous system involvement in patients with cancer. Lancet Neurol 6:75–86.  https://doi.org/10.1016/S1474-4422(06)70679-2 CrossRefPubMedGoogle Scholar
  53. 53.
    Ho MY, Mackey JR (2014) Presentation and management of docetaxel-related adverse effects in patients with breast cancer. Cancer Manag Res 27:253–259.  https://doi.org/10.2147/CMAR.S40601 CrossRefGoogle Scholar
  54. 54.
    Penson RT, Daniels KJ, Lynch TJ (2004) Too old to care? Oncologist 9:343–52CrossRefPubMedGoogle Scholar
  55. 55.
    Surbone A, Kagawa-Singer M, Terret C et al (2006) The illness trajectory of elderly cancer patients across cultures: SIOG position paper. Ann Oncol 18:633–638  https://doi.org/10.1093/annonc/mdl178 CrossRefPubMedGoogle Scholar
  56. 56.
    Turner NJ, Haward RA, Mulley GP et al (1999) Cancer in old age—is it inadequately investigated and treated? BMJ 319:309–312CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Neuroscience UnitInstituto Nacional de Cancerología, Ciudad de MéxicoMexico CityMexico
  2. 2.Geriatric UnitInstituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránCiudad de MéxicoMexico

Personalised recommendations